Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients

scientific article published on 31 December 2014

Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2967/JNUMED.114.141887
P8608Fatcat IDrelease_o4k6sblyifdvresx4jjs3m7ay4
P698PubMed publication ID25552670
P5875ResearchGate publication ID270289148

P50authorLaura EvangelistaQ52983502
Anna Rita CervinoQ53065838
Duccio VolterraniQ59660510
Eugenio BorsattiQ84071666
Giulia PucciniQ114332164
P2093author name stringGiuliano Mariani
Jure Fettich
Marina Hodolič
Giorgio Saladini
Marino Cimitan
Michele Gregianin
Federica Guidoccio
Tanja Baseric
Valentina Bodanza
P433issue2
P407language of work or nameEnglishQ1860
P304page(s)209-215
P577publication date2014-12-31
P1433published inThe Journal of Nuclear MedicineQ7743608
P1476titleGleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients
P478volume56

Reverse relations

cites work (P2860)
Q9072118018F-Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers
Q9212812018F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment
Q5009935218F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study
Q52983532A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
Q38833159Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis
Q44453209Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
Q52984262Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
Q50721465Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT.
Q42257970Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
Q38766102Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.
Q47965751Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score
Q89823517Imaging for Metastasis in Prostate Cancer: A Review of the Literature
Q56358992Imaging of Prostate Cancer Using Fluciclovine
Q41829682Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent
Q52411549Molecular imaging of prostate cancer.
Q52982373No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
Q55395878Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment.
Q39242140PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies
Q39003089PSMA PET and Radionuclide Therapy in Prostate Cancer
Q57110351Positron emission tomography in prostate cancer: An update on state of the art
Q37427275Predictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?
Q90387663Prostate cancer imaging: when the game gets tough, the hard one gets done!
Q34522627Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Q49908509The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?
Q33625389Update on advances in molecular PET in urological oncology

Search more.